Media coverage about Cellectis (NASDAQ:CLLS) has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.7372433596792 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- Tale of the Ticker: Cellectis SA (CLLS) Moves on Volume – Financial News Review (finnewsreview.com)
- Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center NEW YORK–(BUSINESS WIR… (4-traders.com)
- Five Star Senior Living Inc. (FVE) and Cellectis SA (CLLS) closes with a move of -3.18% – Stocks Gallery (stocksgallery.com)
A number of research firms have recently weighed in on CLLS. Zacks Investment Research cut Cellectis from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. BidaskClub cut Cellectis from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of Cellectis in a report on Saturday, June 3rd. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $47.00 price target on shares of Cellectis in a report on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $41.80.
Shares of Cellectis (NASDAQ CLLS) traded up 0.92% during midday trading on Friday, reaching $22.02. The company had a trading volume of 68,318 shares. The firm’s 50 day moving average price is $24.74 and its 200-day moving average price is $23.57. The company’s market capitalization is $789.68 million. Cellectis has a 12 month low of $16.09 and a 12 month high of $28.77.
COPYRIGHT VIOLATION WARNING: “Cellectis (NASDAQ:CLLS) Receives News Impact Score of 0.18” was first reported by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://rinconhillneighbors.org/2017/08/19/cellectis-nasdaqclls-earning-somewhat-positive-press-coverage-study-finds-updated-updated.html.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with our FREE daily email newsletter.